Victory Capital Management Inc. Sells 294 Shares of Atrion Co. (NASDAQ:ATRI)

Victory Capital Management Inc. cut its stake in shares of Atrion Co. (NASDAQ:ATRI) by 12.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,052 shares of the medical instruments supplier’s stock after selling 294 shares during the quarter. Victory Capital Management Inc. owned approximately 0.12% of Atrion worth $928,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Penn Mutual Asset Management LLC purchased a new position in Atrion during the fourth quarter valued at approximately $1,949,000. Public Employees Retirement System of Ohio purchased a new position in shares of Atrion during the 1st quarter valued at $2,299,000. Jump Financial LLC purchased a new position in shares of Atrion during the 4th quarter valued at $234,000. Sei Investments Co. boosted its holdings in Atrion by 59.7% in the 1st quarter. Sei Investments Co. now owns 1,774 shares of the medical instruments supplier’s stock worth $822,000 after buying an additional 663 shares during the period. Finally, Quadrant Capital Group LLC purchased a new stake in Atrion in the 4th quarter worth $36,000. 66.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Atrion in a research report on Thursday. They issued a “sell” rating on the stock.

Atrion Stock Performance

NASDAQ ATRI opened at $459.92 on Friday. Atrion Co. has a 12 month low of $274.98 and a 12 month high of $503.24. The stock has a market cap of $809.46 million, a PE ratio of 43.23 and a beta of 0.69. The stock’s 50 day moving average is $458.90 and its 200 day moving average is $444.77.

Atrion (NASDAQ:ATRI) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 EPS for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The firm had revenue of $48.77 million for the quarter.

Atrion Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.